

ASX: ALA

Arovella Therapeutics Limited
ACN 090 987 250

**ASX Release**

9 September 2026

Dear Shareholder

ANNUAL GENERAL MEETING (2026 AGM)

Notice is hereby given that the 2026 AGM of Arovella Therapeutics Limited (Arovella or the Company) will be held (Meeting or 2026 AGM) at 11.00am (AEDT) on Wednesday, 4 November 2026. The Meeting will be held online at <https://investor.automic.com.au/> and in person at the offices of MinterEllison, Level 20, Collins Arch, 447 Collins Street Melbourne VIC 3000.

Arovella advises that in accordance with sections 110C-110K of the Corporations Act 2001 (Cth), no hard copy of the Notice of Annual General Meeting and Explanatory Notes (Notice) will be circulated other than to shareholders who have expressly requested a hard copy. These documents can be accessed on the Company's website at <https://www.arovella.com/asx-announcements> and via the ASX Market Announcements Platform under the Company's ASX Code (ALA).

If you have nominated an email address and elected to receive electronic communications from the Company, you will receive an email with a link to an electronic copy of the Notice of Meeting.

Director Nominations

Under Listing Rule 3.13.1, the Company advises that the closing date for director nominations is Wednesday, 16 September 2026.

Your Vote is Important

The business of the 2026 AGM is important to all Shareholders and therefore it is important that Shareholders vote. Lodging a completed proxy is the simplest way to vote at the AGM.

The Company encourages shareholders to submit their votes in advance of the 2026 AGM as this will provide the Company with the best opportunity to prepare for the meeting. However, votes may also be submitted during the 2026 AGM. Proxy forms can be lodged online, by post or in person by following the proxy lodgement instructions on the proxy form. Proxy forms must be received by the Company's share registry, Automic, by 11am (AEDT) on Monday, 2 November 2026. Proxy forms received later than this time will be invalid.

If it becomes necessary or appropriate to make alternative arrangements for the holding or conducting of the 2026 AGM, the Company will make further information available through the ASX Market Announcements Platform and on its website.

Shareholder Communication Elections

Recent changes to the Corporations Act provide for shareholders electing and requesting to receive documents (including notices of meeting and the annual financial report) electronically or in hard copy. You

ASX: ALA

Arovella Therapeutics Limited
ACN 090 987 250



can make a standing election and/or request to receive some or all of your communications from the Company in physical or electronic form.

Shareholders can also elect not to receive certain documents, including the annual financial report.

We encourage you to provide your email address so we can communicate with you electronically and you are provided with information regarding the Company more efficiently and sustainably.

If you have made a prior election or request to receive documents in a certain manner then that election will continue to apply until such time as you notify the Company that you change your election or request. Any shareholder who has not made a prior election and/or request to receive documents in a certain form will be treated by the Company as having elected to receive all documents in electronic form.

If you wish to update your communication preference, please refer to the insert titled "Update your details" or contact our share register, Automic below:

Shareholder queries in relation to the Meeting

Shareholders can contact the Company's Registry with any questions prior to the meeting via email listed below.

Telephone (within Australia): 1300 288 664

Telephone (outside Australia): +61 2 9698 5414

Email: hello@automicgroup.com.au

Website: <https://investor.automic.com.au/>

Yours faithfully

Lachlan Mallia

Company Secretary

Arovella Therapeutics Ltd

investor@arovella.com

Release authorised by the Arovella Limited Board of Directors.

FURTHER INFORMATION

Dr Nicole Van Der Weerden

Acting Chief Executive Officer

E nvanderweerden@arovella.com

M +61 407 039 983

David Williams

Chairman

E dwilliams@kidder.com.au

M + 61 414 383 594

ASX: ALA

Arovella Therapeutics Limited
ACN 090 987 250



NOTES TO EDITORS:

About Arovella Therapeutics Ltd

Arovella Therapeutics Ltd (ASX: ALA) is focused on developing its invariant natural killer T (iNKT) cell therapy platform licensed from Imperial College London to treat blood cancers, solid tumours, and autoimmune disease. Arovella's lead product is ALA-101. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. iNKT cells also contain an invariant T cell receptor (iTTCR) that targets glycolipid bound CD1d, another antigen found on the surface of several cancer types. ALA-101 has had its Investigational New Drug application (IND) accepted by the US FDA and is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. Arovella is also expanding into solid tumour treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Arovella will also incorporate its IL-12-TM technology into its solid tumour programs.

Glossary: **iNKT cell** – invariant Natural Killer T cells; **CAR** – Chimeric Antigen Receptor that can be introduced into immune cells to target cancer cells; **TCR** – T cell receptors are a group of proteins found on immune cells that recognise fragments of antigens as peptides bound to MHC complexes; **B-cell lymphoma** – A type of cancer that forms in B cells (a type of immune system cell); **CD1d** – Cluster of differentiation 1, which is expressed on some immune cells and cancer cells; **aGalCer** – alpha-galactosylceramide is a specific ligand for human and mouse natural killer T cells. It is a synthetic glycolipid.

For more information, visit www.arovella.com